Minerva Neurosciences (NERV) Net Income towards Common Stockholders (2013 - 2026)

Minerva Neurosciences' Net Income towards Common Stockholders history runs 14 years deep, the most recent figure standing at -$32.3 million for Q1 2026.

• Quarterly Net Income towards Common Stockholders fell 762.9% year-over-year to -$32.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$44.0 million (down 143.59% YoY) and the FY2025 annual result came in at -$113.8 million, up 2.4% from the prior year.
• Net Income towards Common Stockholders was -$32.3 million for Q1 2026 at Minerva Neurosciences, down from -$5.7 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at -$2.7 million in Q3 2025 and bottomed at -$103.7 million in Q4 2023.
• A 5-year average of -$18.0 million and a median of -$5.9 million in 2024 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders soared 95.83% — and 2026, when it slumped 762.9%.
• Minerva Neurosciences' Net Income towards Common Stockholders stood at -$94.9 million in 2022, then decreased by 9.27% to -$103.7 million in 2023, then surged by 95.83% to -$4.3 million in 2024, then slumped by 31.8% to -$5.7 million in 2025, then sank by 466.37% to -$32.3 million in 2026.
• Business Quant data shows NERV's Net Income towards Common Stockholders at -$32.3 million in Q1 2026, -$5.7 million in Q4 2025, and -$2.7 million in Q3 2025.